Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cystic periventricular leukomalacia in preterm infants: Clinical risks and heart rate and oxygenation patterns.

American journal of perinatology·2026
Same author

Design and initial characterization of a novel mini-promoter for gene therapies targeting the central nervous system.

Molecular therapy. Advances·2026
Same author

AI-guided automated identification of patients at high risk for hepatocellular carcinoma in large US and global datasets.

JHEP reports : innovation in hepatology·2026
Same author

Age at type 2 diabetes diagnosis and risk of cancer: Cohort study in over 1 million individuals from the TriNetX US Collaborative Network.

Journal of diabetes and its complications·2025
Same author

Predicting Dexamethasone-Associated Extubation Success in Preterm Infants.

American journal of perinatology·2025
Same author

A machine learning approach for automating review of a RxNorm medication mapping pipeline output.

Journal of biomedical informatics·2025
Same journal

Rule-Based Algorithm to Identify Recurrent Non-Hodgkin Lymphoma in Electronic Health Data.

JCO clinical cancer informatics·2026
Same journal

Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101.

JCO clinical cancer informatics·2026
Same journal

Effect of a Multidimensional Digital Health Intervention on Quality of Life in Breast Cancer Survivors: A Randomized Controlled Trial.

JCO clinical cancer informatics·2026
Same journal

Can Small Open-Source Language Models With Retrieval-Augmented Generation Match GPT-4 Performance in Breast Cancer Clinical Decision Support?

JCO clinical cancer informatics·2026
Same journal

Machine Learning Algorithm for the Detection of Tumor Microsatellite Instability Based on Multiomics Biomarkers.

JCO clinical cancer informatics·2026
Same journal

Foundation Model-Driven Regions of Interest Classification and Renaming in Cancer Radiotherapy: A Customizable, Retraining-Free Workflow Across Institutions.

JCO clinical cancer informatics·2026
See all related articles

Related Experiment Video

Updated: Jul 13, 2025

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.0K

Exploring Breast Cancer Systemic Drug Therapy Patterns in Real-World Data.

Julia O'Rourke1, Jeff Warnick1, John Doole1

  • 1TriNetX, LLC, Cambridge, MA.

JCO Clinical Cancer Informatics
|October 18, 2023
PubMed
Summary
This summary is machine-generated.

Real-world breast cancer treatment shows common medication patterns aligning with NCCN guidelines, but with some variability in drug administration and cycles used in clinical practice.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.1K

Related Experiment Videos

Last Updated: Jul 13, 2025

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.0K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.1K

Area of Science:

  • Oncology
  • Pharmacology
  • Health Informatics

Background:

  • Breast cancer treatment involves complex medication regimens.
  • Understanding real-world drug administration is crucial for optimizing patient care.
  • Variability in treatment patterns can impact efficacy and patient outcomes.

Purpose of the Study:

  • To analyze real-world medication use and administration patterns in breast cancer patients.
  • To compare observed treatment regimens with established clinical guidelines.
  • To identify common drug administration sequences and their variations.

Main Methods:

  • Retrospective analysis of deidentified patient data from the TriNetX network (2013-2022).
  • Utilized rule-based and unsupervised learning (k-means clustering) to extract medication data and administration patterns.
  • Classified patients by cancer stage (early vs. late) and receptor status (HR+/ERBB2-, ERBB2+, TN) for analysis.
  • Compared derived regimens against National Comprehensive Cancer Network (NCCN) guidelines.

Main Results:

  • Common regimens identified for early-stage HR+/ERBB2- and TN breast cancer included cyclophosphamide/docetaxel and cyclophosphamide/doxorubicin followed by paclitaxel.
  • For early-stage ERBB2+/HR± breast cancer, carboplatin/docetaxel with trastuzumab and potentially pertuzumab was frequent.
  • Observed medication use, number of administrations, and cycle lengths generally aligned with NCCN recommendations across 7,798 patients.

Conclusions:

  • Real-world breast cancer medication administration generally aligns with NCCN guidelines.
  • Variability exists in specific drug choices and administration schedules in clinical practice.
  • Further research can explore the impact of this variability on treatment outcomes.